Bausch Health acquires U.S. rights to Eton Pharmaceuticals’ EM-100

Bausch Health Companies () and Bausch + Lomb, and Eton Pharmaceuticals (ETON) announced a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals’ EM-100, an investigational eye drop that, if approved, will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis. EM-100 has been submitted to the U.S. FDA for review. Eton Pharmaceuticals previously reported positive top-line results from a Phase 3 trial in which EM-100 demonstrated statistically significant superiority to placebo and no adverse events, and demonstrated non-inferiority to a comparator product in the treatment of ocular itching.

https://thefly.com/landingPageNews.php?id=2865941